Predict your next investment

Corporation
onxeo.com

See what CB Insights has to offer

Partners & Customers

8

About Onxeo

Onxeo (Paris: ONXEO) is a developer of orphan oncology drugs. The company is focused on developing therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo's first approved orphan oncology drug, Beleodaq.

Onxeo Headquarter Location

49 boulevard du General Martial Valin

Paris, 75015,

France

+33 (0)1 45 58 76 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Onxeo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Onxeo in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Onxeo News

Onxeo : Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

Oct 14, 2021

10/14/2021 | 01:01pm EDT Message : *Required fields Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent members Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Dr Robert L. Coleman and Dr Jacques Mallet as independent members of the Board of Directors. Robert L. Coleman, MD, is the Chief Scientific Officer of US Oncology Network (“The Network”), one of the U.S. largest networks dedicated to advancing high-quality, evidence-based cancer care and research, with more than 400 clinical studies underway and gathering over 1400 physicians. Prior to joining the US Oncology Network in 2020, Dr Coleman served as executive director of MD Anderson's Cancer Network Research Program. Additionally, he was a professor and also served as the Ann Rife Cox Chair in Gynecology at The University of Texas. Dr Coleman's work has been featured in over 500 publications focusing on the role of novel therapies in ovarian cancer, such as the incorporation of PARP inhibitors in the treatment strategy. Jacques Mallet, MD, served as SVP - Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed or private companies in the health technology sector. He brings to Onxeo more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy and a unique insight gained in life sciences both in Europe and the United States as a venture capitalist. Prior to this, Mr Mallet had been responsible for investments at Auriga Partners, a key life sciences specialized private-equity firm in France, and held some executive positions in global consulting firms such as Monitor Deloitte and Accenture. Dr Robert L. Coleman, new independent member of the Board of Directors of Onxeo, declared: "I am very honored to join the Board of Directors of Onxeo. As a cancer specialist, I have dedicated my entire career to improving the way we treat several types of cancer and I’m thrilled to bring my experience to support the development of Onxeo and its pipeline internationally, notably through clinical development in the United-States. Based on the extensive dataset collected so far by the team, I believe AsiDNA™ could change cancer treatment paradigm, especially in some selected combinations and represents a promising way to help patients in need.” Dr Jacques Mallet, new independent member of the Board of Directors of Onxeo, added: "I’m delighted to have the opportunity of joining this strong group of Directors to support the team in the development and growth of the company. I have been impressed by AsiDNA™ and the numerous development opportunities of this potential breakthrough compound. I am now eager to support Onxeo highly professional teams to best design the next steps to ensure optimal value creation for the company.” Shefali Agarwal, Chairwoman of the Board of Directors of Onxeo, commented: "We are proud to have such distinguished experts join our Board and to benefit from their rich experience in the healthcare industry. Dr Coleman is an internationally recognized leader in ovarian cancer who strongly contributed to developing many innovative treatments for this highly aggressive form of cancer. Dr Mallet brings three decades of experience as strategist and investor in healthcare business, which is a strong asset for Onxeo’s development. Their complementary background combining outstanding clinical research and management of international pharmaceutical companies make them an excellent fit for Onxeo as we continue to grow and enhance our research program around AsiDNA™.” Judith Greciet, Chief Executive Officer of Onxeo, concluded: "I am delighted to welcome these two outstanding experts to our Board. Together with the recent appointment of Shefali Agarwal as our Chairwoman, they will be an active support for the Company’s ambitious development program, including its expansion into the United States.” About Onxeo Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. platON™ is Onxeo’s chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline. AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated clinical stage candidate in the field of DNA Damage Response (DDR). Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumoral properties, notably the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and a strong synergy with tumor DNA-damaging agents such as radio/chemotherapy. AsiDNA™ is currently in combination clinical studies in hard-to-treat solid tumors. OX401 is a new drug candidate from platON™, optimized to be a potent PARP agonist acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies. For more information, please visit www.onxeo.com . Forward looking statements This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group ( www.onxeo.com ) and/or the AMF ( www.amf-france.org ). View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005936/en/ © Business Wire 2021

Onxeo Acquisitions

3 Acquisitions

Onxeo acquired 3 companies. Their latest acquisition was DNA Therapeutics on February 29, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/29/2016

Seed VC

$991

$1.1M

Acquired

2

5/22/2014

Subscribe to see more

$99M

Subscribe to see more

10

5/22/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/29/2016

5/22/2014

5/22/2014

Investment Stage

Seed VC

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$1.1M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Onxeo Partners & Customers

8 Partners and customers

Onxeo has 8 strategic partners and customers. Onxeo recently partnered with Institut Curie on February 2, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

2/4/2021

Partner

Institut Curie

France

1

4/16/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/29/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/24/2017

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/31/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/4/2021

4/16/2020

1/29/2020

4/24/2017

1/31/2017

Type

Partner

Licensee

Partner

Licensee

Partner

Business Partner

Institut Curie

Country

France

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Onxeo Team

2 Team Members

Onxeo has 2 team members, including former Chief Financial Officer, Piers J Morgan.

Name

Work History

Title

Status

Gilles Avenard

Founder

Current

Piers J Morgan

Chief Financial Officer

Former

Name

Gilles Avenard

Piers J Morgan

Work History

Title

Founder

Chief Financial Officer

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.